BIOMAT Database Logo BIOMAT Database Logo

Synthesis and biological evaluation of novel pyrrolidine-2,5-dione inhibitors as potential anti-tumour agents. 1995

S Ahmed, and J H Smith, and P J Nicholls, and R Whomsley, and P Cariuk
Department of Pharmacy, Brighton University, UK.

Several novel pyrrolidine-2,5-dione based compounds have been synthesised and evaluated for their biological activity against human placental aromatase (AR), rat testicular 17 alpha-hydroxylase/17,20-lyase (P450(17) alpha) and bovine cholesterol side chain cleavage (CSCC). The compounds showed good inhibition towards AR with 1-cyclohexyl-3-[2'(4"-aminophenyl) ethyl] pyrrolidine-2,5-dione (3) (IC50 = 23.8 +/- 4.6 microM) and 1-octyl-3-[2'(4"-aminophenyl) ethyl] pyrrolidine-2,5-dione (4) (IC50 = 24.6 +/- 1.8 microM) showing equipotent activity with Aminoglutethimide (AG) (IC50 = 20.0 +/- 2.6 microM, Ki = 11.0 +/- 2.0 microM). Of the compounds tested for P450(17) alpha activity, 3 (IC50 = 18.5 +/- 1.9 microM) again showed the highest activity, being equipotent to Ketoconazole (IC50 = 12.1 +/- 2.9 microM). 3 was a poor inhibitor of CSCC with some 22% inhibitory activity at an inhibitor concentration of 200 microM, as compared to AG with 72% inhibitory activity under the same conditions. The compounds proved themselves to be excellent lead compounds and supported the novel models developed by Ahmed for AR and P450(17) alpha.

UI MeSH Term Description Entries
D008297 Male Males
D010920 Placenta A highly vascularized mammalian fetal-maternal organ and major site of transport of oxygen, nutrients, and fetal waste products. It includes a fetal portion (CHORIONIC VILLI) derived from TROPHOBLASTS and a maternal portion (DECIDUA) derived from the uterine ENDOMETRIUM. The placenta produces an array of steroid, protein and peptide hormones (PLACENTAL HORMONES). Placentoma, Normal,Placentome,Placentas,Placentomes
D002786 Cholesterol Side-Chain Cleavage Enzyme A mitochondrial cytochrome P450 enzyme that catalyzes the side-chain cleavage of C27 cholesterol to C21 pregnenolone in the presence of molecular oxygen and NADPH-FERRIHEMOPROTEIN REDUCTASE. This enzyme, encoded by CYP11A1 gene, catalyzes the breakage between C20 and C22 which is the initial and rate-limiting step in the biosynthesis of various gonadal and adrenal steroid hormones. CYP11A1,Cholesterol Desmolase,Cholesterol Monooxygenase (Side-Chain-Cleaving),Cytochrome P-450 CYP11A1,Cytochrome P-450(scc),20,22-Desmolase,CYP 11A1,Cytochrome P450 11A1,Cytochrome P450scc,20,22 Desmolase,Cholesterol Side Chain Cleavage Enzyme,Cytochrome P 450 CYP11A1
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000311 Adrenal Glands A pair of glands located at the cranial pole of each of the two KIDNEYS. Each adrenal gland is composed of two distinct endocrine tissues with separate embryonic origins, the ADRENAL CORTEX producing STEROIDS and the ADRENAL MEDULLA producing NEUROTRANSMITTERS. Adrenal Gland,Gland, Adrenal,Glands, Adrenal
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013254 Steroid 17-alpha-Hydroxylase A microsomal cytochrome P450 enzyme that catalyzes the 17-alpha-hydroxylation of progesterone or pregnenolone and subsequent cleavage of the residual two carbons at C17 in the presence of molecular oxygen and NADPH-FERRIHEMOPROTEIN REDUCTASE. This enzyme, encoded by CYP17 gene, generates precursors for glucocorticoid, androgen, and estrogen synthesis. Defects in CYP17 gene cause congenital adrenal hyperplasia (ADRENAL HYPERPLASIA, CONGENITAL) and abnormal sexual differentiation. 17 alpha-Hydroxylase,17,20-Lyase,CYP17,Cytochrome P-450(17 alpha),P450(c17),Steroid 17 alpha-Monooxygenase,Steroid 17-Hydroxylase,Steroid 17-Monooxygenase,17 alpha-Hydroxylase Cytochrome P-450,17 alpha-Hydroxyprogesterone Aldolase,17,20-Desmolase,Cytochrome P-450(17-alpha),Cytochrome P450(17 alpha),Hydroxyprogesterone Aldolase,Steroid 17 alpha-Hydroxylase,Steroid-17-Hydroxylase,17 alpha Hydroxylase,17 alpha Hydroxylase Cytochrome P 450,17 alpha Hydroxyprogesterone Aldolase,17 alpha-Hydroxylase, Steroid,17 alpha-Monooxygenase, Steroid,17,20 Desmolase,17,20 Lyase,17-Hydroxylase, Steroid,17-Monooxygenase, Steroid,17-alpha-Hydroxylase, Steroid,Aldolase, 17 alpha-Hydroxyprogesterone,Aldolase, Hydroxyprogesterone,Steroid 17 Hydroxylase,Steroid 17 Monooxygenase,Steroid 17 alpha Hydroxylase,Steroid 17 alpha Monooxygenase,alpha-Hydroxyprogesterone Aldolase, 17,alpha-Monooxygenase, Steroid 17
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D013388 Succinimides A subclass of IMIDES with the general structure of pyrrolidinedione. They are prepared by the distillation of ammonium succinate. They are sweet-tasting compounds that are used as chemical intermediates and plant growth stimulants. Butanimides,Pyrrolidinediones

Related Publications

S Ahmed, and J H Smith, and P J Nicholls, and R Whomsley, and P Cariuk
Synthesis and biological evaluation of novel pyrrolidine-2,5-dione derivatives as potential antidepressant agents. Part 1.
May 2013, European journal of medicinal chemistry,
S Ahmed, and J H Smith, and P J Nicholls, and R Whomsley, and P Cariuk
Synthesis and Biological Evaluation of Pyrazoline and Pyrrolidine-2,5-dione Hybrids as Potential Antitumor Agents.
October 2020, ChemMedChem,
S Ahmed, and J H Smith, and P J Nicholls, and R Whomsley, and P Cariuk
Synthesis and biological evaluation of 3-(prop-2-enyl)- and 3-(prop-2-ynyl)pyrrolidine-2,5-dione derivatives as potential aromatase inhibitors.
February 1996, The Journal of pharmacy and pharmacology,
S Ahmed, and J H Smith, and P J Nicholls, and R Whomsley, and P Cariuk
Synthesis, analysis and biological evaluation of novel indolquinonecryptolepine analogues as potential anti-tumour agents.
March 2016, Organic & biomolecular chemistry,
S Ahmed, and J H Smith, and P J Nicholls, and R Whomsley, and P Cariuk
Design, synthesis, and evaluation of novel galloyl pyrrolidine derivatives as potential anti-tumor agents.
March 2006, Bioorganic & medicinal chemistry,
S Ahmed, and J H Smith, and P J Nicholls, and R Whomsley, and P Cariuk
Facile synthesis and biological evaluation of tryptamine-piperazine-2,5-dione conjugates as anticancer agents.
August 2021, RSC advances,
S Ahmed, and J H Smith, and P J Nicholls, and R Whomsley, and P Cariuk
Pyrrolidine-2,5-dione.
September 2012, Acta crystallographica. Section E, Structure reports online,
S Ahmed, and J H Smith, and P J Nicholls, and R Whomsley, and P Cariuk
Synthesis, structure-activity relationship and biological evaluation of 2,4,5-trisubstituted pyrimidine CDK inhibitors as potential anti-tumour agents.
January 2013, European journal of medicinal chemistry,
S Ahmed, and J H Smith, and P J Nicholls, and R Whomsley, and P Cariuk
Synthesis and biological evaluation of 2,5-diaminobenzamide derivatives as anti-proliferating agents.
June 2009, Archives of pharmacal research,
S Ahmed, and J H Smith, and P J Nicholls, and R Whomsley, and P Cariuk
Pyridazinone derivatives as potential anti-inflammatory agents: synthesis and biological evaluation as PDE4 inhibitors.
April 2021, RSC medicinal chemistry,
Copied contents to your clipboard!